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 ABSTRACT 
 PURPOSE:  To assess the cost-effectiveness of a ceramide-infused skin barrier (CIB) versus other skin barriers (standard of 
care) among patients who have undergone ostomy creation. 
 DESIGN:  Cost-effectiveness analysis, based on a decision-analytic model that was estimated using data from the ADVOCATE 
(A Study Determining Variances in Ostomy Skin Conditions And The Economic Impact) trial, which investigated stoma-related 
healthcare costs over 12 weeks among patients who recently underwent fecal ostomy, and from other sources. 
 SUBJECTS AND SETTING:  Analysis was based on a hypothetical cohort of 1000 patients who recently underwent fecal ostomy; 
over a 1-year period, 500 patients were assumed to use CIB and 500 were assumed to use standard of care. 
 METHODS:  We adapted a previous economic model to estimate expected 1-year costs and outcomes among persons with a 
new ostomy assumed to use CIB versus standard of care. Outcomes of interest included peristomal skin complications (PSCs) 
(up to 2 during the 1-year period of interest) and quality-adjusted life days (QALDs); QALDs vary from 1, indicating a day of perfect 
health to 0, indicating a day with the lowest possible health (deceased). Subjects were assigned QALDs on a daily basis, with 
the value of the QALD on any given day based on whether the patient was experiencing a PSC. Costs included those related 
to skin barriers, ostomy accessories, and care of PSCs. The incremental cost-effectiveness of CIB versus standard of care 
was estimated as the incremental cost per PSC averted and QALD gained, respectively; net monetary benefi t of CIB was also 
estimated. All analyses were run using the perspective of an Australian payer. 
 RESULTS:  On a per-patient basis, use of CIB was expected over a 1-year period to result in 0.16 fewer PSCs, an additional 0.35 
QALDs, and a savings of A$180 (Australian dollars, US $137) in healthcare costs all versus standard of care. Management with 
CIB provided a net monetary benefi t (calculated as the product of maximum willingness to pay for 1 QALD times additional QALDs 
with CIB less the incremental cost of CIB) of A$228 (US $174). Probabilistic sensitivity analysis was also completed; it revealed 
that 97% of model runs resulted in fewer expected PSCs with CIB; 92% of these runs resulted in lower expected costs with CIB. 
 CONCLUSIONS:  Findings suggest that the CIB is a cost-effective skin barrier for persons living with an ostomy. 
 KEY WORDS:  Cost-effectiveness ,  Costs and cost analysis ,  Economic evaluation ,  Economics ,  Ostomy ,  Postoperative 
complications ,  Surgical stomas . 
 INTRODUCTION 
 Despite advances in stoma surgery and ostomy care, up to 
75% of patients experience postoperative complications. 1 , 2 
Stomal and peristomal complications are attributable to vari-
ous causes including moisture-associated skin damage with ex-
posure to stomal effl  uent, mechanical trauma to the peristomal 
skin or hair follicles (eg, stripping injury and pressure injuries) 
due to the ostomy system or ostomy accessories, immunologic 
responses (hypersensitivity or allergic), and infections. 2-5 One 
study estimated that peristomal skin complications (PSCs) ac-
count for 40% of all visits to ostomy care nurses. 6 Over an ap-
proximate 7-week treatment period, a panel of 11 experienced 
stoma care nurses estimated the costs of treatment of PSCs 
to range from €23.10 (US $26.80) for mild cases to €141.20 
(US $163.79) for severe cases (all assume typical care rendered 
in France and are in 2011 Euros). 7 Martins and colleagues 8 
estimated the cost of these complications in the United King-
dom (all assumed to last 7 weeks) to range from ₤106.29 (US 
$139.24) for mild PSCs caused by mechanical trauma to 
₤618.69 (US $810.48) for severe, disease-related PSCs. Given 
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their prevalence and associated cost, ostomy patient instruc-
tion should include strategies to prevent PSCs and maintain 
peristomal skin health.
A novel barrier (CeraPlus) with Remois technology (Alcare 
Co Ltd, Sumida-ku, Tokyo, Japan) is currently marketed by 
Hollister, Inc (Libertyville, Illinois). This ceramide-infused 
barrier (CIB) is designed to maintain adhesive properties 
and features a formulation to help maintain healthy peristo-
mal skin, decrease transepidermal water loss from damaged/
eroded skin, and help protect the skin’s natural moisture bar-
rier.9-11 The ADVOCATE (A Study Determining Variances in 
Ostomy Skin Conditions And The Economic Impact) trial, a 
double-blind randomized controlled study, enrolled 153 adult 
subjects who were randomly allocated to use the CIB versus 
an alternative, currently marketed, barrier (New Image Flex-
Wear or New Image Flextend, Hollister, Incorporated) as a 
control.12 The primary outcome was ostomy-related healthcare 
costs (ie, costs related to “typical” ostomy products such as 
skin barriers and select ostomy accessories plus costs related to 
PSC care). Subjects wore the control or experimental pouches 
over a 12-week period, and patients who experienced PSCs 
were followed up over an additional 4-week “resolution peri-
od” during which all PSC-related costs were captured. Analysis 
revealed that the mean total healthcare costs during follow-up 
were A$36.46 (US $27.89) less among patients randomized 
to the ceramide-infused barrier (n = 79) versus the control 
barrier (n = 74) (A$223.73 vs A$260.19; US $171.14 vs US 
$199.03; P = .017). The cost differences were primarily due 
to differences in ostomy accessory use. In addition, 55.4% of 
subjects allocated to the CIB experienced PSCs versus 40.5% 
of control subjects (P = .069).
Findings from the ADVOCATE trial were limited to a 12-
week follow-up period, and the cost-effectiveness of the CIB ver-
sus other barriers over a longer period is not known. To address 
this limitation, we developed a decision-analytic model to assess 
the cost-effectiveness of the CIB versus other skin barriers within 
a hypothetical cohort of 1000 Australians with fecal ostomies 
over a 360-day period (approximately 1 year); analyses were un-
dertaken within the context of the Australian healthcare system 
and differences were analyzed using Australian dollars (A$).
METHODS
The cost-utility model used in this study compared anticipated 
outcomes and costs among 2 cohorts of ostomy patients; the 
first group used the CIB and the second used other commer-
cially available barriers (standard of care, SoC). We assumed 
that SoC barriers represented any number of barriers from 
multiple manufacturers and were selected following discussion 
between patients and their care providers. The model includ-
ed various ostomy accessories used during typical ostomy care 
and during the management of PSCs. The time horizon for 
our analysis was 360 days. The model allows for the possibil-
ity of 2 PSCs in the year (ie, one during weeks 1-12 and the 
other during weeks 13-52) and differing levels of PSC severity. 
Health-related quality of life was assessed via quality-adjusted 
life days (QALDs), accounting for the differential impact on 
quality of life of varying severity levels of PSCs. The model 
also included both deterministic and probabilistic sensitivity 
analyses (DSA and PSA, respectively). In the DSA various in-
puts were varied one at a time in order to identify the factor(s) 
to which the model was most (or least) sensitive. In the PSA, 
a large number of input values were varied simultaneously, 
allowing an examination of the sensitivity of results to the 
overall level of uncertainty in model inputs. A schematic of 
the model is presented in Figure 1.
The model compared expected costs associated with an un-
complicated ostomy, increased use of pouching supplies and 
accessories during PSCs, other healthcare services required 
to treat and manage PSCs, and daily use of accessories sub-
sequent to PSC resolution in persons using a CIB or an SoC 
pouching system. The difference in expected healthcare costs 
between these 2 scenarios is expressed as the incremental cost 
(barrier and PSC management). Similar calculations were used 
to estimate total expected QALDs and the incremental differ-
ences between use of the CIB versus SoC. Key assumptions of 
this model are summarized in Table 1.
Cost-Utility Model
Hypothetical participants entered the model having under-
gone fecal stoma surgery within the past 12 weeks, and they 
were discharged home using either a CIB pouching system or 
a SoC system. Given that the percentage of 1- and 2-piece 
users in Australia is approximately 50%, the distribution of 
subjects in ADVOCATE (in which only 2-piece products were 
used) between CIB and SoC was also applied to 1-piece us-
ers (Table 2). Pouching supply use was based on information 
collected during the ADVOCATE trial, which is described in 
greater detail elsewhere.12 The costs of pouching supplies for 
SoC were based on publicly available information from the 
Australian healthcare system13; we assumed that the costs of 
pouching supplies for CIB were equal to those of SoC, since in 
Australia barriers in each category (ie, 1- and 2-piece systems) 
are priced at parity.
The model we used also accounted for accessory use (eg, 
flat rings, ostomy belts, and adhesive remover spray) by means 
of an “average accessory use profile,” percentages of patients 
assumed to use each accessory, and the corresponding num-
ber of units and cost per package. Accessory use, shown in 
Table 3, was assumed to depend on the number of times pa-
tients change their pouching supplies.
Incidence of Peristomal Complications
The annual probability of PSCs for CIB and SoC was based 
on information from the ADVOCATE trial, as was the sever-
ity distribution of the initial PSC. Because only 2 patients ex-
perienced 2 PSCs in ADVOCATE (both allocated to the SoC 
group), the trial could not be used to estimate the probability 
Figure 1. Model diagram. PSC indicates peristomal skin compli-
cation.
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of a second PSC. In the absence of this information, we kept 
the 5% absolute difference in risk observed in ADVOCATE 
consistent and assumed that 15% of SoC patients and 10% 
of CIB patients would experience a second PSC. We also 
assumed, irrespective of barrier used, that use of additional 
accessories following an initial PSC would reduce the risk 
of a second PSC by 50%. All baseline values related to PSC 
incidence and the accompanying severity distribution are pre-
sented in Table 4, and were taken from the ADVOCATE trial 
unless otherwise noted.
Findings from the ADVOCATE trial indicated that the av-
erage time to PSC resolution was 18 days for mild cases (de-
fined as a Discoloration, Erosion, Tissue overgrowth [DET] 
instrument score <4), 33 days for moderate cases (defined as a 
DET score >4 and <7), and 33 days for severe cases (defined 
as a DET score ≥7). The time to PSC resolution was assumed 
to be equal in both arms.
Cost of treatment of PSC included additional pouching 
supplies and healthcare services until projected resolution. In-
formation on use of pouching supplies during PSCs is set forth 
in Table 5, including use of 1- and 2-piece systems. For 2-piece 
systems, use of baseplates during PSCs was allowed to vary 
at a level potentially different from that of 1-piece pouches. 
Estimates are provided by PSC severity and by barrier received 
TABLE 1.
Key Assumptions Used to Construct Cost-effectiveness Model
Assumption Description
1 Patients can experience up to 2 PSCs during the 1-y time horizon
2 PSCs occur either on d 42 (the middle of the first 12-wk period) or on d 224 (the midpoint of wk 12-52 of the 1-y time horizon)
3 Only patients who experience a PSC on d 42 can experience a second PSC during the 1-y time horizon
4 65% of initial PSCs occur on d 42; the remaining 35% of initial PSCs occur on d 224 (ie, the model assumes that patients have a higher likelihood of PSC 
development relatively early following stoma creation)
5 Increases in use of PSC-related pouching supplies and accessories last from PSC onset until PSC resolution
6 Time to PSC resolution is dependent on its severity
7 Patients who experience a PSC can add accessories to their daily regimen following PSC resolution if they are not already using accessories at PSC onset
8 Costs of accessories added after PSC resolution are incurred from the date of resolution until the end of the model time horizon
9 Irrespective of PSC occurrence, switching from CIB to SoC or vice versa is not allowed
Abbreviations: CIB, ceramide-infused skin barrier; PSC, peristomal skin complication; SoC, standard of care.
TABLE 2.
Use and Cost of Pouching Supplies
Name
Patients Using the Pouching 
Supply, n (%)a Component
Average Changes per Week 
per Patient, n Package Cost, A$ Units/Package
SoC
One-piece
 Flat open (drainable) 88 (17.5) System 7 146.40 30
 Convex open (drainable) 163 (32.5) System 7 65.80 10
Two-piece
 Flat 88 (17.5) Baseplate
Pouch
3.2
3.2
23.71
36.60
 5
10
 Convex 163 (32.5) Baseplate
Pouch
3.2
3.2
29.20
36.30
 5
10
Ceramide-infused skin barrier
One-piece
 Flat open 83 (16.5) System 7 146.40 30
 Convex open 168 (33.5) System 7 65.80 10
Two-piece
 Flat 83 (16.5) Baseplate
Pouch
2.9
2.9
23.71
36.60
 5
10
 Convex 168 (33.5) Baseplate
Pouch
3.3
3.3
29.20
36.30
 5
10
Abbreviation: SoC, standard of care.
aNumbers and percentages are based off of a hypothetical cohort of 500 patients
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(ie, CIB or SoC). Information on use of healthcare services, 
including additional visits to a healthcare provider such as an 
ostomy nurse or physician, and ostomy accessories such as 
an ostomy belt or powder is summarized in Table 6. As with 
pouching supplies, this information is categorized based on 
PSC severity and barrier received. Data from the ADVOCATE 
trial were used to inform estimates of pouching supplies and 
healthcare services used during a PSC (while ADVOCATE 
did not evaluate 1-piece pouching systems, were assumed 
that these barriers would perform similarly from their 2-piece 
counterparts). Based on usage patterns in Australia and sup-
plies provided by the Australian healthcare system, CIB and 
SoC barriers were both assumed to be changed once daily. 
Costs for medical resources were taken from the Stoma Ap-
pliance Scheme Schedule (2017).13 Quality-adjusted life days 
represent participants’ daily quality of life; a value of 1 refers 
to 1 day in perfect health, and a value of 0 refers to worst pos-
sible health (deceased). Patients were assigned 1 of 4 possible 
QALD values daily based on no PSC (subsequently referred 
to as an uncomplicated ostomy), mild PSC, moderate PSC, 
or severe PSC (Table 7). For example, given a QALD value of 
0.754 for an uncomplicated ostomy (no PSC), a QALD value 
for mild PSC of 0.697, and a duration of mild PSC of 18 days, 
a patient who experiences 1 mild PSC would accumulate a 
total of 274.18 QALDs over a 1-year period (ie, [365 – 18] 
× 0.754 + [18 × 0.697]). Similarly, given the assumed value 
associated with a day spent with no PSC, the maximum num-
ber of QALDs a patient could accumulate over a 1-year period 
TABLE 4.
Incidence and Severity of PSCsa
Parameter SoC CIB
Annual probability of PSC 55% (41/74) 41% (32/79)
Proportion of patients who experience a second PSC, among patients who already experienced a PSC, without addition 
of accessory
15% 10%
Reduction in the incidence of a second PSC with the addition of an accessoryb 50% 50%
Probability first PSC is mild 69% (28/41) 72% (23/32)
Probability first PSC is moderate 29% (12/41) 25% (8/32)
Probability first PSC is severe 2% (1/41) 3% (1/32)
Probability second PSC is mild, given first PSC is mild 0% (0/1) 33%c
Probability second PSC is moderate, given first PSC is mild 100% (1/1) 33%c
Probability second PSC is severe, given first PSC is mild 0% (0/1) 34%c
Probability second PSC is mild, given first PSC is moderate 0% (0/1) 33%c
Probability second PSC is moderate, given first PSC is moderate 100% (1/1) 33%c
Probability second PSC is severe, given first PSC is moderate 0% (0/1) 34%c
Probability second PSC is mild, given first PSC is severe 33%c 33%c
Probability second PSC is moderate, given first PSC is severe 33%c 33%c
Probability second PSC is severe, given first PSC is severe 34%c 34%c
Abbreviations: CIB, ceramide-infused skin barrier; PSC, peristomal skin complication; SoC, standard of care.
aNumerators and denominators are in parentheses.
bADVOCATE Study did not provide input on this parameter. Both ceramide-infused skin barrier and SoC values were assumed to be 50% to be conservative.
cNo values were observed in ADVOCATE; these values are assumptions.
TABLE 3.
Accessory Use
Medical Resource Package Cost, A$ Units/Package Units Used/wka Unit Cost, A$
Patients Using 
the Accessory, %
Average Cost per Patient Using 
Accessory/wk, A$b
SoC CIB SoC CIB
Flat ring 45.30 10 5.1 4.53 47 33 10.86 7.60
Paste 11.28 20 5.1 0.56 39 28 1.12 0.80
Ostomy belt 5.98 90 5.1 0.07 31 19 0.11 0.06
Adhesive remover spray 10.23 50 5.1 0.20 29 35 0.30 0.36
Skin film wipes 14.50 50 5.1 0.29 25 24 0.37 0.35
Ostomy powder 8.70 50 5.1 0.17 20 17 0.18 0.15
Abbreviations: CIB, ceramide-infused skin barrier; SoC, standard of care.
aCalculated as the average of the number of ostomy system changes per week, weighted by the proportions receiving 1- and 2-piece systems, respectively (see Table 2 for the proportions and 
changes).
bCalculated by multiplying units used per week times unit cost times the percentage of patients using the accessory. Average daily cost per patient for SoC is calculated based on the average 
number of daily pouching supply changes calculated from the baseplate change frequency summarized in Table 2.
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is 275.21 (ie, 365 × 0.754). We acknowledge that estimates 
from the ADVOCATE trial were influenced by the effects of 
surgery and postsurgical recovery such as impaired social activ-
ities, reduced satisfaction with life, feelings of social isolation, 
and need of emotional support.14 We further acknowledge that 
health-related quality of life may also be impacted by nonsur-
gical factors, such as changes in work life or relationship with a 
partner/spouse.15 Because our focus was the decrement specific 
to experiencing PSCs, utility decrements were based on a sep-
arate, substantially larger study, the Pouch Impact Assessment 
by Hollister, which included 3123 patients with ostomy.16 In 
this study, the sum of QALDs during days spent with or with-
out a PSC was calculated to derive the total expected QALDs 
per patient over the 360-day period.
Data Analysis
Expected PSCs, costs (including those related to PSC-related 
care and ostomy-related care), and QALDs, respectively, were 
estimated for both CIB and SoC subjects. The incremental 
cost-effectiveness ratio of CIB versus SoC was reported as in-
cremental cost per PSC avoided and number of QALD gained. 
The net monetary benefit was also calculated, using the formula 
(E ×λ) – C,17 where E is the expected benefit of CIB (in terms 
of the expected incremental gain in QALDs relative to SoC); 
λ, the willingness-to-pay threshold (assumed to be A$50,000/
QALY, or A$136.89/QALD [ie, A$50,000/365.25]); and C is 
the anticipated incremental cost of CIB (vs SoC).
Deterministic and probabilistic sensitivity analyses were 
performed. For both analyses, we varied the following parame-
ters: annual incidence of PSC with SoC and CIB; severity mix 
for first and second PSCs; days to PSC resolution; percentage 
of patients using accessories at model entry; QALD decre-
ments by PSC severity; percentage increase in use of pouching 
supplies for 1- and 2-piece system baseplates and 2-piece sys-
tem pouches; percentage of patients using each type of med-
ical care at PSC onset; and percentage increase in accessory 
use after a PSC. In the probabilistic sensitivity analysis, the 
increase in accessory supplies was capped at 240% (ie, a sce-
nario representing more than a twofold increase in accessory 
use relative to base case estimates), to exclude unrealistically 
high accessory supply usage during PSC. In the deterministic 
sensitivity analysis, each parameter was varied one at a time, 
TABLE 5.
Percentage Increase in Pouching Supply Use Until PSC Resolutiona
PSC Severity Mild Moderate Severe
Pouching Supplies SoC CIB SoC CIB SoC CIB
Increase in the use of initial pouching supplies, 1-piece systems (until healing), % 64 29 49 83 49 83
Increase in the use of initial pouching supplies—baseplate, 2-piece systems (until healing), % 64 29 49 83 49 83
Increase in the use of initial pouching supplies—pouch, 2-piece systems (until healing) 64 29 49 83 49 83
Abbreviations: CIB, ceramide-infused skin barrier; PSC, peristomal skin complication; SoC, standard of care.
aEstimates presented herein are relative increases, and are applied to patterns of use during time without PSC shown in Tables 2 and 3.
TABLE 6.
Direct Medical Care Use by PSC Severity by Barrier Receiveda
Medical Resource
Patients, %
Mild Moderate  Severe
SoC CIB SoC CIB SoC CIB
STN
 First visit 100.0 100.0 100.0 100.0 100.0 100.0
 Second visit 100.0 100.0 100.0 100.0 100.0 100.0
 Third visit 100.0 100.0 100.0 100.0 100.0 100.0
 Fourth visit 14.3 8.7 16.7 50.0 0.0 0.0
Physician (first visit) 3.6 4.3 8.3 0.0 0.0 0.0
Ostomy belt 14.4 17.0 25.0 13.0 0.0 0.0
Facility fee (x3)b 100.0 100.0 100.0 100.0 100.0 100.0
Facility fee (x1)b 14.0 8.7 16.7 50.0 0.0 0.0
Adhesive spray 21.0 13.0 42.0 25.0 100.0 0.0
Adhesive remover 32.1 43.5 25.0 12.5 0.0 0.0
Topical antibiotic 3.6 8.8 0.0 0.0 0.0 0.0
Ostomy powder 43.0 35.0 58.0 50.0 0.0 100.0
Film wipes 36.0 13.0 50.0 38.0 0.0 100.0
Abbreviations: CIB, ceramide-infused skin barrier; SoC, standard of care; STN, stomal therapy nurse.
aValues are taken from the ADVOCATE study; percentages estimated based on subjects enrolled in ADVOCATE. A total of 28, 12, and 1 SoC patients experienced mild, moderate, and severe 
PSCs, respectively; corresponding values for ceramide-infused skin barrier were 23, 8, and 1, respectively.
bFacility fee (x3) is the facility fee associated with the first 3 STN visits. Facility fee (x1) is the facility fee associated with the fourth STN visit.
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savings with CIB of A$106 (US $82); reducing the proportion 
of SoC patients on these supplies resulted in expected cost sav-
ings with CIB of A$241 (US $186, Figure 2). Among the clini-
cal parameters, the most influential one on the cost savings was 
the probability of experiencing a PSC with the use of SoC. Re-
ducing this parameter value to 44% from the base case value of 
55% reduced the cost savings to A$125 (US $96.70). Estimates 
of expected incremental cost savings were most sensitive to the 
percentage of patients using the CIB or SoC and the proportion 
using flat ring accessories (the most expensive accessory).
In the probabilistic sensitivity analyses, we completed 2000 
runs, each using different values for the various model inputs. 
Each run was plotted in Figure 3 based on its expected incre-
mental benefit (ie, expected QALDs gained with CIB – expected 
QALDs gained with SoC) and the expected incremental cost. 
Results of these analyses indicated that use of CIB was ex-
pected to result in fewer PSCs in 97% of simulations, lower 
healthcare costs in 92% of simulations, reduce both PSCs and 
healthcare costs in 90% of simulations, and increased QALDs 
in 61% of simulations (Figure 3). Given a willingness-to-pay 
threshold of A$136.89/QALD (US $105.41/QALD), repre-
sented by the diagonal line (typically used in these diagrams 
to indicate the threshold below which an intervention is con-
sidered cost-effective) as seen in Figure 3, CIB was preferred 
over SoC in approximately 92.2% of the simulations. In more 
than half of these simulations (55.3%), CIB was expected 
to yield equal or greater QALDs at equal or lower cost. In 
contrast, CIB was expected to yield greater QALDs at higher 
cost in 3.75% of simulations. In 33.5% of simulations, CIB 
was expected to yield fewer QALDs at lower cost; however, 
the additional QALDs expected with SoC exceeded the 
willingness-to-pay ratio.
Scenario Analyses
We completed 2 scenario analyses; one assumed the same se-
verity distributions of PSCs for CIB and SoC, and the oth-
er varied the likelihood of a PSC and its severity based on 
findings from the ADVOCATE trial.2 In the scenario where 
we assumed PSC severity distributions were equal, CIB use 
was expected to create a cost reduction of A$88,083 (US 
$67,824). The anticipated cost reduction on a per-patient 
basis was A$176 (US $136) and the expected QALD scores 
were 158 and 0.32, respectively. In the scenario where the 
only differences between CIB and SoC were in incidence and 
severity of PSCs, CIB resulted in expected per-patient cost 
savings of A$76 (US $59) and a QALD gain of 0.34. In sum-
mary, both scenarios favored use of the CIB.
DISCUSSION
Results from our model suggest that use of a CIB among per-
sons with a new fecal ostomy is expected to result in lower costs, 
results in fewer PSCs, and modestly increased QALDs. These 
findings were consistent across various sensitivity analyses, as 
well as 2 relatively conservative scenarios that assumed a parity 
across treatment arms not observed in ADVOCATE.12 Assum-
ing that 25% of the approximate 40,000 Australians living with 
fecal ostomy used the CIB, we project a 1-year cost saving to 
the Australian healthcare system of approximately A$1,800,762 
(US $1,386,587). We also project that persons with an ostomy 
who switch to the CIB would experience 1643 fewer PSCs.
The primary function of an ostomy barrier is to prevent 
water loss through the epidermis, and to prevent stoma effluent 
with the base case values changed to the respective upper and 
lower 95% confidence interval bounds. For the probabilistic 
sensitivity analyses, we ran the model 2000 times, each time 
simultaneously replacing parameter estimates for any included 
variable with an alternative value derived by sampling from its 
underlying distribution.
We also ran 2 scenario analyses: 1 in which severity distribu-
tion of PSCs associated with CIB use was assumed to be equal to 
those of SoC, and 1 in which all parameters for CIB save those 
related to incidence and severity of PSCs were set equal to osto-
my management using an SoC pouching system. As noted earli-
er, all analyses were conducted from the perspective of the Aus-
tralian healthcare system; expected costs are presented as both 
Australian dollars (A$) and US dollars (US$). Because the model 
was based on living with an ostomy for 360 days, we did not 
discount either outcomes or costs. This decision was based on 
guidelines for development of this type of economic model.18,19
RESULTS
In the cohort of 500 hypothetical new ostomy patients 
created for this model, use of CIB over a 360-day period 
is expected to decrease ostomy- and PSC-related costs by 
A$90,038 (US $69,329), increase (all versus SoC) QALDs 
by 174, and reduce the number of PSCs by 82 (Table 8). 
On a per-patient basis, CIB was expected to result in health-
care cost savings of A$180 (US $139), 0.35 additional 
QALDs, and 0.16 fewer PSCs. Given the expected reduc-
tion in healthcare costs and increase in QALDs, CIB yield-
ed better outcomes at lower cost when compared to SoC. 
The corresponding net monetary benefit to the Australian 
healthcare system associated with use of CIB versus SoC was 
A$227.91 (US $175.49) (i.e. [a willingness-to-pay thresh-
old of A$136.89/QALD × 0.35 additional QALDs] – the 
incremental savings of CIB of A$180). Based on our find-
ings and assuming approximately 40,000 Australians living 
with a fecal ostomy,20 a switch of 25% to CIB could re-
sult in 1643 fewer PSCs and a cost saving of A$1,800,762 
(US $1,386,587) over a 360-day period.
Sensitivity Analyses
Results of the deterministic sensitivity analyses suggested that 
use of CIB in lieu of SoC would lower healthcare costs under 
multiple potential scenarios within the model we created. For 
example, increasing the proportion of SoC patients on relative-
ly low-cost pouching supplies to 27% resulted in expected cost 
TABLE 7.
QALDs for Health States
Health State/Event SoC (SE)
Ceramide-Infused  
Skin Barrier (SE)
Uncomplicated ostomy 0.754 (0.006) 0.754 (0.006)
Decrement per PSC eventa
Mild PSC −0.057 (0.004) −0.057 (0.004)
Moderate PSC −0.107 (0.008) −0.107 (0.008)
Severe PSC −0.165 (0.016) −0.165 (0.016)
Abbreviations: PSC, peristomal skin complication; QALD, quality adjust life days; SE, standard 
error; SoC, standard of care. 
aTo estimate QALDs per PSC event, subtract the decrement associated with the relevant 
PSC event from the uncomplicated ostomy value (eg, the QALD for mild PSC is 0.697, or 
0.754-0.057).
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from permeating into the skin and initiating an irritative or 
immune response. Compromise of the skin barrier of an os-
tomy pouching system changes the lipid composition of the 
peristomal skin.23-25 The model we created extrapolates results 
of the ADVOCATE trial over a 360-day period in an attempt 
to demonstrate potential benefits and associated costs. The 
majority of simulations (1849 out of 2000 or 92.4%) we 
completed resulted in lower expected costs and fewer PSCs 
TABLE 8.
Basecase Results
Outcome
Aggregate Cohort (n = 1000) Per-Patient Basis
CIB (n = 500) SoC (n = 500) Δ CIB SoC Δ
Number of PSCs 215 297 −82 0.595 0.431 −0.164
Healthcare costs, A$
Usual ostomy care
 One-piece systems 541,710.00 538,650.00 3,060 1,083.42 1,077.30 6.120
 Two-piece systems—baseplate 224,361.44 224,463.09 −102 448.72 448.93 −0.203
 Two-piece systems—pouches 147,855.09 149,348.57 −1,493 295.71 298.70 −3
 Accessories 175,239.09 219,526.92 −44,288 350.48 439.05 −88.576
 Total usual ostomy care 1,089,166 1,131,989 −42,823 2,178.33 2,263.98 −85.65
PSC-related
 Pouching supplies
  One-piece systems 8,736 13,759 −5,022 17.47 27.52 −10.04
  Two-piece systems—baseplate 3,685 5,816 −2,131 7.37 11.63 −4.26
  Two-piece systems—pouches 2,090 3,205 −1,115 4.18 6.41 −2.23
  Total pouching supplies 14,512 22,780 −8,268 29.02 45.56 −16.54
 Accessories
  Flat ring 719 27,718 −26,999 1.44 55.44 −54.00
  Paste 15,011 2,864 −12,147 30.02 5.73 24.29
  Ostomy belt 1,586 268 −1,318 3.17 0.54 2.64
  Adhesive remover spray 699 772 −74 1.40 1.54 −0.15
  Skin film wipes 127 944 −817 0.25 1.89 −1.63
  Ostomy powder 297 453 −156 0.59 0.91 −0.31
  Total accessories 18,438 33,019 −14,580 36.88 66.04 −29.16
 Direct medical care
  Physician (first visit) 555.51 1,308.56 −753.05 1.11 2.62 −1.51
  STN 27,287.06 37,229.70 −9,942.64 54.57 74.46 −19.89
  Ostomy belt 196.01 315.90 −119.89 0.39 0.63 −0.24
  Facility feea 27,458.68 37,441.07 −9,982.39 54.92 74.88 −19.96
  Adhesive spray 1,187.01 3,149.28 −1,962.27 2.37 6.30 −3.92
  Adhesive remover 741.90 884.26 −142.36 1.48 1.77 −0.28
  Topical antibiotic 81.06 41.70 39.36 0.16 0.08 0.08
  Ostomy powder 781.67 1,224.71 −443.04 1.56 2.45 −0.89
  Film wipes 766.50 1,826.86 −1,060.36 1.53 3.65 −2.12
  Total direct medical care 59,055 83,422 −24,367 118.11 166.84 −48.73
 Total PSC-related 92,005 139,221 −47,215 184 278 −94
Total healthcare costs, A$ 1,181,171 1,271,209 −90,038 2,362.34 2,542.42 −180.08
QALDs 135,363 135,189 174 270.73 270.38 0.35
Abbreviations: CIB, ceramide-infused skin barrier; PSC, peristomal skin complication; STN, stomal therapy nurse; QALD, quality-adjusted life day; SoC, standard of care.
aFacility fee is the facility fee associated with the all STN visits.
Copyright © 2017 Wound, Ostomy and Continence Nurses Society™. Unauthorized reproduction of this article is prohibited.Copyright © 2018 The Authors. Published by Wolters Kluwer Health, Inc.  
on behalf of the Wound, Ostomy and Continence Nurses Society™. Unauthorized reproduction of this article is prohibited.
JWOCN ¿ Volume 45  ¿  Number 2  153Berger et al
in persons using the CIB (1947 out of 2000 runs, or 97.3%). 
In comparison, fewer simulations (1214 out of 2000 or 
60.7%) resulted in increased QALDs. These seemingly dis-
crepant findings are a result of allowing both the incidence 
and severity of PSCs to vary simultaneously, which resulted in 
scenarios where CIB use was associated with fewer but more 
severe and/or moderate PSCs relative to SoC skin barrier use. 
When the probabilistic sensitivity analyses was run with a 
fixed PSC severity distribution, 98% of simulations (1960 
out of 2000 runs) resulted in increased QALDs with use of 
the CIB. Accordingly, while CIB was preferred in 92% of the 
simulations (1840/2000 runs), only 59% of runs indicated 
that CIB was expected to provide equal or greater QALDs at 
a lower cost or at a higher cost that did not exceed the willing-
ness-to-pay ratio of A$136.89/QALD (US$105.41/QALD). 
Because QALD is the benefit used in estimating the incre-
mental cost-effectiveness ratio, it is not surprising that CIB 
was deemed cost-effective in approximately 59% of the runs. 
While there is evidence to suggest that the current willing-
ness-to-pay threshold we used may be lower than that reflect-
ed in reality,26 it is unlikely that an increased threshold would 
increase the proportion of simulations in which CIB would 
be deemed cost-effective (Figure 2). In the other 33.15% 
of the 2000 simulations in which CIB use emerged as cost- 
effective, it was expected to yield fewer QALDs as compared 
to SoC; however, the incremental cost associated with SoC 
in those scenarios exceeded the willingness-to-pay threshold. 
We note that if the measure of cost-effectiveness was defined 
Figure 2. Expected incremental cost of ceramide-infused skin barrier versus SoC in deterministic sensitivity analyses. The vertical dotted 
black line represents incremental per patient cost savings associated with use of ceramide-infused skin barrier in the base case (A$180). 
Negative estimates indicate expected cost savings associated with use of ceramide-infused skin barrier instead of SoC. acc indicates 
accessories; add, addition; bp, baseplate; CIB, ceramide-infused skin barrier; inc, increase; pce, piece; pr, probability; ps, pouching 
supplies; SoC, standard of care; sys, system.
Figure 3. Incremental costs and QALDs associated with use of ceramide-infused skin barrier versus SoC in probabilistic sensitivity 
analyses. PSA indicates probabilistic sensitivity analysis; QALD, quality-adjusted life day; SoC, standard of care. Note: Each point on 
the figure is the result of one of a total of 2000 runs of the model, each implemented with a different set of input values. Each point 
represents the incremental benefit (estimated as total expected QALDs with CIB – total expected QALDs with SoC) and incremental 
cost (estimated as total expected cost with CIB – total expected cost with SoC) associated with use of CIB versus SoC. Results are 
expressed on a per-patient basis.
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based on averted PSCs (vs increased QALDs), CIB would 
likely be preferred in more than 90.3% of simulations, al-
though a definitive conclusion is difficult without knowledge 
of the Australian government’s willingness-to-pay threshold 
to avert a PSC.
Limitations
Our study has several limitations. As with all economic models, 
several assumptions were required to develop our model. We 
assumed that patients could experience no more than 2 PSCs 
within the time horizon, and that those PSCs would occur at 
the midpoints of weeks 1 to 12 and weeks 13 to 52. Howev-
er, the timing of these events may differ in clinical practice. 
Jonkers and colleagues27 observed that 82% of consecutive pa-
tients (n = 100) who underwent ostomy surgery experienced 
complications within the subsequent year, with “skin irrita-
tion” being the most common (55% of the cohort, 67% of 
the subgroup who experienced complications). In their study 
of 180 persons with ostomies, Persson and colleagues28 noted 
that complications were observed as early as 2 weeks follow-
ing surgery. Persson’s group also reported a total of 303 stoma 
complications over 2 years (an average of 1.68 complications 
per patient); 94% of these complications occurred during the 
first year following surgery. Accordingly, we may have under-
estimated the risk of PSCs; both in terms of the initial risk of 
having a PSC and the risk of subsequent events. In addition, 
our model also did not differentiate between ostomy types (eg, 
colostomy and ileostomy), surgical approach, and other factors 
likely to influence the incidence of PSCs.
We also assumed that the cost of CIB was equal to that 
of SoC to be consistent with the Australian healthcare system 
that prices all barriers in the same category at parity. While 
this rendered our analyses consistent with current reimburse-
ment practices in Australia, it has a large impact on findings, 
as reductions in the costs of PSCs are not offset by increased 
cost of ostomy supplies. Therefore, the impact of any subse-
quent price modifications to ostomy products (either CIB or 
other skin barriers) on the expected cost-effectiveness of CIB 
would require separate analysis. While the ADVOCATE trial 
did not assess 1-piece pouching systems, we included them in 
our assessment in an effort to better reflect “real-world” use 
of ostomy systems. Evidence concerning the performance of 
1- and 2-piece systems is absent, and caution is warranted in 
interpretation of our findings with respect to the performance 
of 1- versus 2-piece pouching systems.
We assumed that PSCs were of fixed duration. While this 
simplified the model, it also placed “caps” on the cost and 
health-state burden associated with these PSCs. As other studies 
have reported longer resolution times ranging from 7 weeks7,8 to 
more than 3 months,29 we may have underestimated the cumu-
lative costs of PSCs, and consequently, the expected cost-effec-
tiveness of regular use of CIB relative to SoC pouching systems.
In addition, parameter estimations used in our model were 
based in large part on findings from the ADVOCATE trial. 
While enormously helpful in providing estimates of the inci-
dence of PSCs and costs thereof, the trial is limited in terms of 
the overall number of enrollees and the duration of follow-up. 
Accordingly, we were required to make several assumptions 
concerning events that occurred in weeks 13 to 52. While 
we believe them reasonable, analyses would be more robust 
if these assumptions were replaced by additional “real-world” 
data that reflect the experience of new ostomates over the pe-
riod of interest.
Finally, we assumed that decisions to use specific healthcare 
resources could only be made at certain times during the 1-year 
period of interest. For example, we assumed that patients 
would not switch from a CIB to another (SoC) pouching 
system or vice versa regardless of whether they experienced a 
PSC. Similarly, we assumed that the only time accessory use 
would change was following a PSC, and that once changed, it 
would remain at those levels until the end of the time horizon. 
These assumptions may have increased estimates of expected 
total healthcare costs of patients who experienced PSCs. How-
ever, the degree to which patients in clinical practice use acces-
sories as prophylaxis for subsequent PSCs is unknown.
CONCLUSIONS
Based on the model presented in this study, we found that use 
of a CIB pouching system resulted in a per-patient healthcare 
cost savings of A$180 (US $138.60), along with a gain of 0.35 
QALDs and 0.16 fewer PSCs. Findings were consistent across 
a number of sensitivity analyses, and more than 90% of simu-
lations projected lower costs and fewer PSCs with use of the ce-
ramide-infused barrier. Our analyses therefore suggest that the 
CIB is a cost-effective choice of skin barrier for persons with a 
new fecal ostomy when used over an extended period of time.
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